

Expanding horizons for patients with Pompe disease: Using data to guide clinical practice


Practice aid for the management of people living with Pompe disease For more information, visit: <u>www.touchendocrinologyime.org</u> Practice aid for the management of people living with Pompe disease

Real-world data highlight ongoing unmet needs in Pompe disease

Wiedian (() onset to 5.4	Diagnosis to ERT initiation to ERT years
Diagnoses prior to LOPD diagnosis:71%53%53%Symptoms, signs and abnormal clinical/laboratory findings not classified elsewhereEndocrine, nutritional and metabolic diseasesNervous system diseases	41% Respiratory system diseases
US RWE highlights disease burden in ERT-treated patients: ²	
Unmet needs in Healthcare needs on 12-month Respiratory 85	LOPD (n=55) 79
Pompe disease: Insights from Ambulatory 57	54
RWE burden are complex not comorbidities, GI 68	33
CV 17	29
Cumulative incidence of most comorbidities, notably respiratory infections, increased over time US RWE highlights ERT-related treatment burden in Pompe disease: ^{2,3}	
Treatment burden remains a challenge Outpatient visits and ERT prescription costs were key contributors to the economic burden of treatment ³ Healthcare resource utilization and medical visits were substantial, adding to the burden of treatment ³	New treatments are needed to help reduce medical visits, resource use and healthcare costs ³
Supportive service use (occupational, speech and physical therapy) increased over time in IOPD and LOPD ²	
Pompe disease patient registries (e.g. NCT06121011, NCT00231400) ^{4–7} may help to address current knowledge and data gaps	Touch™ ENDOCRINOLOGY

Practice aid for the management of people living with Pompe disease

Current ERT options for Pompe disease are expanding




ENDOCRINOLOGY

Practice aid for the management of people living with Pompe disease

Clinical trials and RWE show ERT switching is a feasible option in Pompe disease


PROPEL study: Switching from AVA + PBO to CIPA + MIG in patients with LOPD showed clinically meaningful improvements¹⁶


Overall proportion of patients with clinically relevant improvement or worsening in 6MWD and/or FVC after switching ERT, with similar safety profiles



Nearly $4 \times$ as many patients who switched to CIPA + MIG **improved** in 6MWD and/or FVC vs those remaining on ALG **Pompe Registry (NCT00231400):** Motor and respiratory outcomes were stable in patients with LOPD switching from ALG to AVA⁶

Mean change in pulmonary measures between visits (pre- and post-ERT switch)





In addition to current and emerging therapies, a need for a multidisciplinary, holistic approach to the care of patients with Pompe disease remains¹⁷

- Patients living with Pompe disease should undergo periodic evaluation and examinations to explore heart, respiratory and muscle function¹⁸
- Follow-up programmes should be tailored to individual patient needs and adjusted to the stage of disease¹⁸

General evaluation¹⁸

Evaluate growth parameters at regular intervals in infants and children (every 3–6 months, depending on age/clinical forms)

Musculoskeletal and functional tests¹⁸

Perform motor and functional assessments every 3–6 months for children aged <5 years, every 6–12 months for older children and adults



MDT considerations¹⁸

- Antibody/biochemical status
- Auditory function
- Anaesthesiology evaluation
- Behaviour/cognitive function
- Bone density
- Cardiology
- GI function
- Neuromuscular evaluation

ENDOCRINOLOGY

- Quality of life
- Respiratory function

Abbreviations and references

Abbreviations

6MWD, 6-minute walk test distance; Ab, antibody; ALG, alglucosidase alfa; AVA, avalglucosidase alfa; CIPA, cipaglucosidase alfa; CV, cardiovascular; EMA, European Medicines Agency; ERT, enzyme replacement therapy; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; GA, general anaesthetic; GAA, acid alpha glucosidase; GI, gastrointestinal; IAR, infusion-associated reaction; IMR, immune-mediated reaction; IOPD, infantile-onset Pompe disease; LOPD, late-onset Pompe disease; MDT, multidisciplinary team; MIG, miglustat; PBO, placebo; PI, prescribing information; pred., predicted; RWE, real-world evidence; SmPC, summary of product characteristics; TEAE, treatment-emergent adverse event.

References

- 1. Nordin S, et al. Presented at 21st Annual WORLDSymposium 2025. San Diego, CA, USA. 3–7 February 2025. Abstr. 248.
- 2. Pillai NR, et al. Presented at 21st Annual WORLDSymposium 2025. San Diego, CA, USA. 3–7 February 2025. Abstr. 119.
- 3. Steiner RD, et al. Presented at 21st Annual WORLDSymposium 2025. San Diego, CA, USA. 3–7 February 2025. Abstr. 331.
- 4. McIntosh P, et al. Presented at 21st Annual WORLDSymposium 2025. San Diego, CA, USA. 3–7 February 2025. Abstr. 225.
- 5. ClinicalTrials.gov. NCT06121011. Available at: https://clinicaltrials.gov/study/NCT06121011 (accessed 10 March 2025).
- 6. Schoser B, et al. Presented at: 29th Annual Congress of the World Muscle Society 2024, Prague, Czechia. 8–12 October 2024. P668.
- 7. ClinicalTrials.gov. NCT00231400. Available at: https://clinicaltrials.gov/study/NCT00231400 (accessed 10 March 2025).
- 8. EMA. Alglucosidase alfa SmPC. Available at: <u>https://bit.ly/3F8L2Ff</u> (accessed 3 March 2025).
- 9. FDA. Alglucosidase alfa PI. Available at: <u>https://bit.ly/3FcFnOA</u> (accessed 3 March 2025).
- 10. EMA. Avalglucosidase alfa SmPC. Available at: <u>https://bit.ly/4bvkZEc</u> (accessed 3 March 2025).
- 11. FDA. Avalglucosidase alfa PI. Available at: <u>https://bit.ly/4iw23aE</u> (accessed 3 March 2025).
- 12. EMA. Cipaglucosidase alfa SmPC. Available at: https://bit.lv/4kuBaFW (accessed 3 March 2025).
- 13. FDA. Cipaglucosidase alfa PI. Available at: <u>https://bit.ly/41xAPcK</u> (accessed 3 March 2025).
- 14. EMA. Miglustat SmPC. Available at: <u>https://bit.ly/4ivSxnU</u> (accessed 3 March 2025).
- 15. FDA. Miglustat PI. Available at: <u>https://bit.ly/4i8N0ns</u> (accessed 3 March 2025).
- 16. Schoser B, et al. Presented at: WORLDSymposium 2025, San Diego, CA, USA. 3–7 February 2025. Abstr. 303.
- 17. Stevens D, et al. Curr Treat Options Neurol. 2022;24:573-88.
- 18. Parenti G, et al. Orphanet J Rare Dis. 2024;19:408.

The guidance provided by this practice aid is not intended to directly influence patient care. Clinicians should always evaluate their patients' conditions and potential contraindications and review any relevant manufacturer product information or recommendations of other authorities prior to consideration of procedures, medications, or other courses of diagnosis or therapy included here.

Our practice aid coverage does not constitute implied endorsement of any product(s) or use(s). touchENDOCRINOLOGY cannot guarantee the accuracy, adequacy or completeness of any information and cannot be held responsible for any errors or omissions.

